- Home
- IRWD vs TLSI Comparison
IRWD vs TLSI Comparison
Compare IRWD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRWD
- TLSI
- Stock Information
- Founded
- IRWD 1998
- TLSI 2010
- Country
- IRWD United States
- TLSI United States
- Employees
- IRWD N/A
- TLSI N/A
- Industry
- IRWD Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- IRWD Health Care
- TLSI Health Care
- Exchange
- IRWD Nasdaq
- TLSI Nasdaq
- Market Cap
- IRWD 150.9M
- TLSI 160.4M
- IPO Year
- IRWD 2010
- TLSI N/A
- Fundamental
- Price
- IRWD $0.63
- TLSI $5.23
- Analyst Decision
- IRWD Buy
- TLSI Strong Buy
- Analyst Count
- IRWD 5
- TLSI 5
- Target Price
- IRWD $4.94
- TLSI $10.90
- AVG Volume (30 Days)
- IRWD 3.0M
- TLSI 43.7K
- Earning Date
- IRWD 05-07-2025
- TLSI 05-15-2025
- Dividend Yield
- IRWD N/A
- TLSI N/A
- EPS Growth
- IRWD N/A
- TLSI N/A
- EPS
- IRWD N/A
- TLSI N/A
- Revenue
- IRWD $317,676,000.00
- TLSI $32,141,000.00
- Revenue This Year
- IRWD N/A
- TLSI $55.13
- Revenue Next Year
- IRWD N/A
- TLSI $50.71
- P/E Ratio
- IRWD N/A
- TLSI N/A
- Revenue Growth
- IRWD N/A
- TLSI 46.20
- 52 Week Low
- IRWD $0.53
- TLSI $3.50
- 52 Week High
- IRWD $7.11
- TLSI $7.75
- Technical
- Relative Strength Index (RSI)
- IRWD 39.10
- TLSI 38.39
- Support Level
- IRWD $0.55
- TLSI $4.95
- Resistance Level
- IRWD $0.65
- TLSI $5.68
- Average True Range (ATR)
- IRWD 0.07
- TLSI 0.37
- MACD
- IRWD 0.02
- TLSI -0.01
- Stochastic Oscillator
- IRWD 37.04
- TLSI 7.69
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.